UTHR (United Therapeutics) Interest Expense: $-16 Mil (TTM As of Mar. 2026)


UTHR United Therapeutics Corp UTHR
88 GF Score
Price $541.81
GF Value $386.40
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is United Therapeutics Interest Expense?

United Therapeutics UTHR -0.57% 88 Interest Expense is $-16 Mil as of Mar. 2026. GuruFocus rates UTHR with a GF Score™ of 88/100 and a GF Value™ of $386.40 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. United Therapeutics's interest expense for the three months ended in Mar. 2026 was $ -3 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-16 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. United Therapeutics's Operating Income for the three months ended in Mar. 2026 was $ 326 Mil. United Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $ -3 Mil. United Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 was 108.60. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

United Therapeutics  (NAS:UTHR) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

United Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $-3 Mil. Its Operating Income for the three months ended in Mar. 2026 was $326 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $0 Mil.

United Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*325.8/-3
=108.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

United Therapeutics Corp has no debt.

United Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for United Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics Interest Expense Chart

United Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.60 -32.40 -59.30 -42.90 -19.50

United Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.10 -7.30 -3.00 -3.10 -3.00
UTHR
88GF Score
United Therapeutics Corp UTHR
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

United Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-16 Mil mean?
United Therapeutics (UTHR) has a Interest Expense of $-16 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on United Therapeutics and its competitors.
Is United Therapeutics' Interest Expense too high?
United Therapeutics' current Interest Expense is $-16 Mil. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Interest Expense compare to VTRS and NBIX?
United Therapeutics' Interest Expense of $-16 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on United Therapeutics and its competitors. United Therapeutics's current Interest Expense is $-16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $386.40, compared to a current price of $541.81 — trading 40.2% above its estimated fair value. The current Interest Expense is $-16 Mil. United Therapeutics' overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For United Therapeutics (UTHR), the current Interest Expense is $-16 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is United Therapeutics (UTHR) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of $541.81 is trading 40.2% above its estimated GF Value™ of $386.40. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for UTHR:

  • Interest Expense: $-16 Mil
  • GF Value™: $386.40 vs. price of $541.81 (40.2% above fair value)
  • GF Score™: 88/100 with 7 warning signs

No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

United Therapeutics Business Description

Other Exchanges UTH:GermanyU2TH34:Brazil
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
88GF Score

Get the complete analysis for UTHR

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$541.81
Price
$386.40
GF Value